Search Results

KALA BIO, Inc. announced that Kim Brazzell, Ph.D., Head of R&D and Chief Medical Officer of KALA BIO, will present at the Jefferies Global Healthcare Conference being held in New York, NY on Wednesday, June 5, 2024 at 12:30 p.m. ET.

KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today reported financial results for the first quarter ended March 31, 2024 and provided a corporate update.

KALA BIO, Inc. today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors for the sale, in a private placement, of shares of its common stock and shares of its Series H Convertible Non-Redeemable Preferred Stock (the “Series H Preferred Stock”), for aggregate gross proceeds of approximately $12.5 million, before deducting offering expenses.

Kala Pharmaceuticals, Inc. today announced that it will change its name to KALA BIO, Inc. effective August 2, 2023, to better reflect the company’s focus on advancing biologics for the treatment of ophthalmic conditions.

KALA BIO, Inc. (NASDAQ:KALA) today announced that Mark Iwicki, Chair and Chief Executive Officer of KALA BIO, will present a corporate overview at the TD Cowen 44th Annual Healthcare Conference being held in Boston on Monday, March 4, 2024 at 12:50 p.m. ET.